Cardiovascular Research Consortium - a Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Atrial Fibrillation
- Sponsor
- University of Turku
- Enrollment
- 1001
- Locations
- 1
- Primary Endpoint
- Atrial fibrillation
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
The objective of CAREBANK study is to establish definitive relationships with human cardiac samples and clinical phenotypes in patients undergoing cardiac procedures. Specifically, the investigators aim at comparing atrial phenotypes from atrial fibrillation patients and controls. The work consists of three broad categories: A) role of atrial cardiomyopathy in atrial fibrillation; B) genetic defects predisposing to atrial fibrillation; and C) the role of inflammation in atrial fibrillation.
Detailed Description
The investigators aim to A) compare atrial cardiomyopathy findings from the tissue samples to clinical phenotype and adverse events B) study the association of genetic defects predisposing to atrial fibrillation with atrial cardiomyopathy findings in the tissue samples C) assess the role of inflammation in atrial fibrillation by comparing circulating cytokine profiles, purinergic signaling and atrial cardiomyopathy findings in tissue samples.
Investigators
Tuomas Kiviniemi
Cardiologist, MD, PhD, FESC
University of Turku
Eligibility Criteria
Inclusion Criteria
- •Any open-heart cardiac surgery
- •Written informed consent
- •All-comers design
Exclusion Criteria
- •No informed consent
Outcomes
Primary Outcomes
Atrial fibrillation
Time Frame: postoperatively until 5 years follow-up
Occurrence of atrial fibrillation
Secondary Outcomes
- All-cause Mortality(postoperatively until 5 years follow-up)
- Transient ischemic attack(postoperatively until 5 years follow-up)
- Stroke(postoperatively until 5 years follow-up)
- Myocardial infarction(postoperatively until 5 years follow-up)
- Target vessel revascularization(postoperatively until 5 years follow-up)
- Post-pericardiotomy syndrome(postoperatively until 1 years follow-up)